New flu shot technology tested in major trial
NCT ID NCT05144945
Summary
This study tested a new type of flu vaccine made using recombinant technology against a standard egg-based flu shot. It involved 301 healthy adults in South Korea to see if the new vaccine triggered a similar or better immune response and was equally safe. The trial was a Phase 3 study, meaning it was a large, late-stage test to gather final evidence before potential approval.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA (HEALTHY VOLUNTEERS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :4100001
Seoul, Seoul-teukbyeolsi, 152-703, South Korea
-
Investigational Site Number :4100002
Seoul, 07441, South Korea
-
Investigational Site Number :4100003
Ansan-si, Gyeonggi-do, 15355, South Korea
Conditions
Explore the condition pages connected to this study.